Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma

Overview of attention for article published in Farmacia Hospitalaria, November 2019

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 7 X posts from 7 X users, with an upper bound of 10,303 followers.

RT @GENESIS_SEFH: Evaluación económica e impacto presupuestario de #mepolizumab en #asma eosinofílica refractaria severa @farm_hosp @Emilio…

RT @GENESIS_SEFH: Evaluación económica e impacto presupuestario de #mepolizumab en #asma eosinofílica refractaria severa @farm_hosp @Emilio…

RT @GENESIS_SEFH: Evaluación económica e impacto presupuestario de #mepolizumab en #asma eosinofílica refractaria severa @farm_hosp @Emilio…

RT @GENESIS_SEFH: Evaluación económica e impacto presupuestario de #mepolizumab en #asma eosinofílica refractaria severa @farm_hosp @Emilio…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.